Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04147728

Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC — Rvision-001  

Stereotactic Body Radiation Therapy Clinical Trial

Official title:
Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in Non-small Cell Lung Cancer：An Exploratory Single-Arm Phase II Clinical Trail

Clinical Trial Summary

The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional edema in non-small cell lung cancer.

Clinical Trial Description

The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with perilesional edema in non-small cell lung cancer. The sample size is 50. Patients start to take Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1~14, day22~36.Edema index will be used to evaluate the effectiveness of Anlotinib. The "Edema index (EI)" is calculated per the equation of "edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04147728
Study type Interventional
Source Peking University Third Hospital
Contact Hongqing Zhuang, doctor
Phone 13051776232
Email hongqingzhuang@163.com
Status Recruiting
Phase Phase 2
Start date December 24, 2019
Completion date December 15, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04161287 - Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
Suspended NCT04020276 - OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases Phase 1
Recruiting NCT04940936 - Shared Decision Making on Radiation Dose for Lung Malignancies N/A
Recruiting NCT05189054 - Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Not yet recruiting NCT05411809 - The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer N/A
Not yet recruiting NCT04351282 - SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma N/A
Recruiting NCT03253536 - Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma N/A
Withdrawn NCT03431415 - Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer N/A
Recruiting NCT05209243 - START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC N/A
Recruiting NCT02545751 - SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer Phase 2
Completed NCT04912128 - Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC
Completed NCT03340974 - Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04512846 - Comparison of Efficacy in SBRT of Large HCC With or Without TACE